Entresto
A pill used to treat certain types of chronic heart failure, when the heart cannot pump or fill with blood properly.
Cosentyx
An injection for inflammatory conditions including psoriasis, some forms of arthritis and a chronic skin disease called hidradenitis suppurativa.
Kisqali
A cancer medicine used with hormone treatment for certain types of breast cancer.
Kesimpta
A monthly self-injection for adults with relapsing forms of multiple sclerosis, a disease in which the immune system damages nerves.
Pluvicto
An intravenous treatment that delivers radioactive particles to certain prostate cancer cells.
Leqvio
An injection given by a health professional to lower low-density lipoprotein (LDL) cholesterol, a type of fat in the blood.
Demonstrações financeiras completas →
Novartis researches, tests, manufactures and sells prescription medicines in about 120 countries (2025, high). Its research focuses on heart, kidney and metabolic diseases, immune disorders, brain and nerve diseases, and cancer. Net sales were USD 54.532 billion (FY2025, high).
Construído a partir dos próprios documentos de Novartis AG entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
The themes Novartis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$ 160,26-0,1%fechamento 12 de nov.
Números até 30 de setembro de 2026, do 6-K arquivado em 27 de outubro de 2026
Novartis sells prescription medicines for heart disease, cancer and immune disorders to drug wholesalers, pharmacies, hospitals and health systems.
Grade A
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Mostrando 2 de 29 trimestres do histórico de notas de Novartis AG. Os outros 27 vão até janeiro de 2018.